0001209191-20-054070.txt : 20201006 0001209191-20-054070.hdr.sgml : 20201006 20201006174824 ACCESSION NUMBER: 0001209191-20-054070 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201005 FILED AS OF DATE: 20201006 DATE AS OF CHANGE: 20201006 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TOMSICEK MICHAEL JOHN CENTRAL INDEX KEY: 0001570392 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 201227691 MAIL ADDRESS: STREET 1: 28 OVERLOOK DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-05 0 0001674416 CRISPR Therapeutics AG CRSP 0001570392 TOMSICEK MICHAEL JOHN C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 86.75 2020-10-05 4 A 0 11666 0.00 A 2030-10-05 Common Shares 11666 11666 D This option was granted on October 5, 2020 with respect to 11,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 5, 2020. /s/ Michael Esposito, attorney-in-fact 2020-10-06